Project Grant HT9425261E363

The Defense Health Agency awarded Proteinqure Inc. $5.6 million on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct a Phase 1 clinical trial evaluating the safety and anticancer activity of PQ203 in patients with breast cancer. The award runs through August 31, 2029, with work performed in Ottawa, Ontario, Canada. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform...

The Defense Health Agency awarded the University of Illinois $750,000 on May 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate the induction of immunogenic cell death and immune-mediated tumor regression of advanced breast cancer through aprepitant, an FDA-approved drug. Work will be performed in Urbana, Illinois, with performance through April 30, 2029. The project grant supports basic, applied, and advanced biomedical research to transform health...

The Defense Health Agency awarded Beckman Research Institute of The City of Hope $140,000 on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to enhance tumor-infiltrating lymphocyte (TIL) trafficking via paired cell engineering and lipid nanoparticle modulation of the tumor microenvironment in mucosal melanoma. The award period runs through August 31, 2027, with work performed at Beckman's facility in Irwindale, California. The Military Medical...

The Defense Health Agency awarded the University of Illinois $1.25 million on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop novel cholesterol-targeting therapies for inflammatory breast cancer. Performance occurs in Chicago, Illinois, with a completion date of June 30, 2029. The award supports basic and applied biomedical research intended to transform health care for Service Members and the American public through innovative therapeutic...

The Defense Health Agency awarded $1.249 million to Icahn School of Medicine at Mount Sinai on May 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop first-in-class degraders targeting oncogenic PTK6 in triple negative breast cancer. Performance runs through April 30, 2029, with work performed in New York, NY 10029. The award supports basic and applied biomedical research aligned with the program's mandate to transform health care for Service Members...

The Defense Health Agency awarded the Beckman Research Institute of the City of Hope $416,217 on September 30, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop photoacoustic computed tomography technology for identifying and diagnosing axillary lymph nodes in breast cancer patients without surgery. Performance runs through September 29, 2029, at the Institute's Irwindale, California research facility. The Military Medical Research and Development program...

The Defense Health Agency awarded the University of California Irvine $750,000 on May 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop a novel strategy to improve the effectiveness of radiation therapy in breast cancer. The award funds research activity from May 1, 2026, through April 30, 2029, with place of performance in Irvine, California. The Military Medical Research and Development program supports basic, applied, and advanced biomedical...

The Defense Health Agency awarded Icahn School of Medicine at Mount Sinai $1.25 million on May 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop first-in-class degraders targeting oncogenic PTK6 in triple negative breast cancer. The award is a project grant with a period of performance through April 30, 2029, and work is performed in New York, NY. The Military Medical Research and Development program supports basic, applied, and advanced biomedical...

The Defense Health Agency awarded Dana-Farber Cancer Institute, Inc. $2 million under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2026, to support the Prostate Cancer Clinical Trials Consortium. The award funds clinical trial coordination and research activities from September 30, 2026, through September 29, 2030, at Dana-Farber's Boston, Massachusetts location. The Military Medical Research and Development program supports basic, applied, and advanced...

The Defense Health Agency awarded the University of California Irvine $140,000 on September 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate SUMO-specific protease 3 as a novel target for improving actinomycin D-based therapies in Wilms tumors. The award is a Project Grant with a period of performance from September 15, 2026, through September 14, 2028. Work is performed in Irvine, California. The Military Medical Research and Development program...